Identification

Name
Salbutamol
Accession Number
DB01001  (APRD00553)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Structure
Thumb
Synonyms
  • Albuterol
Product Ingredients
IngredientUNIICASInChI Key
Salbutamol sulfate021SEF373151022-70-9BNPSSFBOAGDEEL-UHFFFAOYNA-N
Salbutamol tartrateADS4I3E22M661464-94-4VNVNZKCCDVFGAP-FPDJQMMJSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AiromirAerosol, metered100 mcgRespiratory (inhalation)Valeant Canada Lp Valeant Canada S.E.C.1998-08-13Not applicableCanada
Albuterol SulfateSyrup2 mg/5mLOralVista Pharm, Inc.2016-09-07Not applicableUs
Albuterol SulfateSolution.75 mg/3mLRespiratory (inhalation)Mylan Pharmaceuticals2009-10-30Not applicableUs
Albuterol SulfateSolution1.5 mg/3mLRespiratory (inhalation)Mylan Pharmaceuticals2009-10-30Not applicableUs
Asmavent Nebules P.F.Liquid2.5 mgRespiratory (inhalation)Technilab Pharma Inc.1997-06-272001-09-05Canada
Asmavent Respirator Solution Inh 5mg/mlSolution5 mgRespiratory (inhalation)Technilab Pharma Inc.1993-12-312005-08-05Canada
Bci Salbutamol Inhalation SolutionSolution1 mgRespiratory (inhalation)Baker Cummins Inc2005-07-042006-10-03Canada
Bci Salbutamol Inhalation SolutionSolution2 mgRespiratory (inhalation)Baker Cummins IncNot applicableNot applicableCanada
Dom-salbutamol Respirator Solution-1mg/mlSolution1 mgRespiratory (inhalation)Dominion Pharmacal1997-05-16Not applicableCanada
Levalbuterol HydrochlorideSolution1.25 mg/3mLRespiratory (inhalation)The Ritedose Corporation2012-12-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlbuterolTablet4 mg/1OralMylan Institutional1997-04-29Not applicableUs
AlbuterolTablet4 mg/1OralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
AlbuterolTablet2 mg/1OralMylan Pharmaceuticals1991-01-17Not applicableUs
AlbuterolAerosol, metered90 ug/1OralRebel Distributors1996-08-14Not applicableUs
AlbuterolTablet4 mg/1OralMylan Pharmaceuticals1991-01-17Not applicableUs
AlbuterolTablet2 mg/1OralMylan Institutional1997-04-29Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Nucare Pharmaceuticals, Inc.1997-09-17Not applicableUs
Albuterol SulfateTablet2 mg/1Oralbryant ranch prepack1989-12-05Not applicableUs
Albuterol SulfateSolution2.5 mg/3mLRespiratory (inhalation)Physicians Total Care, Inc.2003-10-21Not applicableUs
Albuterol SulfateSyrup2 mg/5mLOcclusive dressing techniqueDispensing Solutions, Inc.1998-01-30Not applicableUs
International/Other Brands
AccuNeb / Aerolin / Asmol / Asthalin / Asthavent / ProAir (Teva) / PROAIRHFA / Proventil / Salamol / Ventilan (GlaxoSmithKline) / Ventolin (GlaxoSmithKline) / Ventoline (GlaxoSmithKline) / VENTOLINHFA / Ventorlin (GlaxoSmithKline) / VoSpire
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-salvent-ipravent SterulesSalbutamol (2.5 mg) + Ipratropium bromide (0.5 mg)SolutionRespiratory (inhalation)Apotex Corporation2006-08-25Not applicableCanada
Combivent Inhalation AerosolSalbutamol sulfate (120 mcg) + Ipratropium bromide (20 mcg)Aerosol, meteredOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1995-12-312007-10-02Canada
Combivent RespimatSalbutamol (100 mcg) + Ipratropium bromide (20 mcg)SolutionRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee2014-09-16Not applicableCanada
Combivent RespimatSalbutamol sulfate (120 ug/1) + Ipratropium bromide (20 ug/1)Spray, meteredRespiratory (inhalation)Boehringer Ingelheim2012-07-01Not applicableUs
Combivent UdvSalbutamol (1 mg) + Ipratropium bromide (0.2 mg)SolutionRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1997-07-25Not applicableCanada
DuoNebSalbutamol sulfate (2.5 mg/3mL) + Ipratropium bromide (.5 mg/3mL)SolutionRespiratory (inhalation)Mylan Specialty2011-02-152016-10-13Us
IpramolSalbutamol (2.5 mg) + Ipratropium bromide (0.5 mg)SolutionRespiratory (inhalation)Ivax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Ipratropium Bromide and Albuterol SulfateSalbutamol sulfate (2.5 mg/3mL) + Ipratropium bromide (.5 mg/3mL)SolutionRespiratory (inhalation)Teva2008-01-02Not applicableUs
Ipratropium Bromide and Albuterol SulfateSalbutamol sulfate (3 mg/3mL) + Ipratropium bromide (.5 mg/3mL)SolutionRespiratory (inhalation)Sandoz2013-05-20Not applicableUs
Ipratropium Bromide and Albuterol SulfateSalbutamol sulfate (2.5 mg/3mL) + Ipratropium bromide (.5 mg/3mL)SolutionRespiratory (inhalation)Proficient Rx LP2013-05-13Not applicableUs
Categories
UNII
QF8SVZ843E
CAS number
18559-94-9
Weight
Average: 239.3107
Monoisotopic: 239.152143543
Chemical Formula
C13H21NO3
InChI Key
NDAUXUAQIAJITI-UHFFFAOYSA-N
InChI
InChI=1S/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3
IUPAC Name
4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
SMILES
CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1

Pharmacology

Indication

For symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.

Structured Indications
Pharmacodynamics

Salbutamol (INN) or albuterol (USAN), a moderately selective beta(2)-receptor agonist similar in structure to terbutaline, is widely used as a bronchodilator to manage asthma and other chronic obstructive airway diseases. The R-isomer, levalbuterol, is responsible for bronchodilation while the S-isomer increases bronchial reactivity. The R-enantiomer is sold in its pure form as Levalbuterol. The manufacturer of levalbuterol, Sepracor, has implied (although not directly claimed) that the presence of only the R-enantiomer produces fewer side-effects.

Mechanism of action

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

TargetActionsOrganism
ABeta-2 adrenergic receptor
agonist
Human
UBeta-1 adrenergic receptor
agonist
Human
UBeta-3 adrenergic receptorNot AvailableHuman
Absorption

Systemic absorption is rapid following aerosol administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate.

Route of elimination

Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite.

Half life

1.6 hours

Clearance
Not Available
Toxicity

LD50=1100 mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Salbutamol.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Salbutamol.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Salbutamol.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Salbutamol.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Salbutamol.Illicit, Withdrawn
AmiodaroneSalbutamol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Salbutamol.Approved
AnagrelideSalbutamol may increase the QTc-prolonging activities of Anagrelide.Approved
Arsenic trioxideSalbutamol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherSalbutamol may increase the QTc-prolonging activities of Artemether.Approved
AsenapineSalbutamol may increase the QTc-prolonging activities of Asenapine.Approved
AtenololAtenolol may decrease the bronchodilatory activities of Salbutamol.Approved
AtomoxetineAtomoxetine may increase the tachycardic activities of Salbutamol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Salbutamol is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Salbutamol is combined with Atosiban.Approved
AzithromycinSalbutamol may increase the QTc-prolonging activities of Azithromycin.Approved
BedaquilineSalbutamol may increase the QTc-prolonging activities of Bedaquiline.Approved
BendroflumethiazideSalbutamol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Salbutamol.Withdrawn
Benzylpenicilloyl PolylysineSalbutamol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Salbutamol.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Salbutamol.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Salbutamol.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Salbutamol.Experimental
BromocriptineBromocriptine may increase the hypertensive activities of Salbutamol.Approved, Investigational
BucindololBucindolol may decrease the vasoconstricting activities of Salbutamol.Investigational
BumetanideSalbutamol may increase the hypokalemic activities of Bumetanide.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Salbutamol.Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Salbutamol.Approved
CabergolineCabergoline may increase the hypertensive activities of Salbutamol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Salbutamol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Salbutamol.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Salbutamol.Approved, Investigational
CeliprololCeliprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
CeritinibSalbutamol may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Salbutamol.Withdrawn
ChloroquineSalbutamol may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideSalbutamol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineSalbutamol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorthalidoneSalbutamol may increase the hypokalemic activities of Chlorthalidone.Approved
CiprofloxacinSalbutamol may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideSalbutamol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramSalbutamol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinSalbutamol may increase the QTc-prolonging activities of Clarithromycin.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Salbutamol.Approved, Vet Approved
CloranololCloranolol may decrease the bronchodilatory activities of Salbutamol.Experimental
ClozapineSalbutamol may increase the QTc-prolonging activities of Clozapine.Approved
CrizotinibSalbutamol may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salbutamol.Approved
CyclopenthiazideSalbutamol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Salbutamol.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Salbutamol.Approved
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Salbutamol.Experimental
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Salbutamol.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Salbutamol.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Salbutamol.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Salbutamol.Approved
DisopyramideSalbutamol may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideSalbutamol may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronSalbutamol may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneSalbutamol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Salbutamol.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Salbutamol.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Salbutamol.Approved
DronedaroneSalbutamol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolSalbutamol may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Salbutamol.Approved
EliglustatSalbutamol may increase the QTc-prolonging activities of Eliglustat.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Salbutamol.Approved
ErgonovineErgonovine may increase the hypertensive activities of Salbutamol.Approved
ErgotamineErgotamine may increase the hypertensive activities of Salbutamol.Approved
ErythromycinSalbutamol may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramSalbutamol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Salbutamol.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Salbutamol.Approved
Etacrynic acidSalbutamol may increase the hypokalemic activities of Etacrynic acid.Approved
FlecainideSalbutamol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluoxetineSalbutamol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolSalbutamol may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Salbutamol.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salbutamol.Approved, Vet Approved
FurosemideSalbutamol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Gadobenic acidSalbutamol may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinSalbutamol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GoserelinSalbutamol may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronSalbutamol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HaloperidolSalbutamol may increase the QTc-prolonging activities of Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Salbutamol.Experimental
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Salbutamol.Experimental
HydrochlorothiazideSalbutamol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideSalbutamol may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbutilideSalbutamol may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneSalbutamol may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Salbutamol.Approved
IndapamideSalbutamol may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Salbutamol.Withdrawn
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Salbutamol.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Salbutamol.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salbutamol.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salbutamol.Approved
LabetalolLabetalol may decrease the vasoconstricting activities of Salbutamol.Approved
LenvatinibSalbutamol may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideSalbutamol may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinSalbutamol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Salbutamol.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Salbutamol.Approved
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Salbutamol.Experimental
LopinavirSalbutamol may increase the QTc-prolonging activities of Lopinavir.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Salbutamol.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Salbutamol is combined with Loxapine.Approved
LumefantrineSalbutamol may increase the QTc-prolonging activities of Lumefantrine.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Salbutamol.Illicit, Withdrawn
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Salbutamol.Withdrawn
MepindololMepindolol may decrease the bronchodilatory activities of Salbutamol.Experimental
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Salbutamol.Experimental
MethadoneSalbutamol may increase the QTc-prolonging activities of Methadone.Approved
MethyclothiazideSalbutamol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Salbutamol.Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Salbutamol.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Salbutamol.Approved
MetolazoneSalbutamol may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Salbutamol.Experimental
MifepristoneMifepristone may increase the QTc-prolonging activities of Salbutamol.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Salbutamol.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Salbutamol.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Salbutamol.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Salbutamol.Approved
MoxifloxacinSalbutamol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NebivololNebivolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Salbutamol.Withdrawn
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Salbutamol.Approved
NilotinibSalbutamol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Salbutamol.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Salbutamol.Withdrawn
OfloxacinSalbutamol may increase the QTc-prolonging activities of Ofloxacin.Approved
OndansetronSalbutamol may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Salbutamol.Investigational
OxprenololOxprenolol may decrease the bronchodilatory activities of Salbutamol.Approved
PaliperidoneSalbutamol may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatSalbutamol may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Salbutamol.Approved
PazopanibSalbutamol may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Salbutamol.Approved, Investigational
PentamidineSalbutamol may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenSalbutamol may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Salbutamol.Approved, Vet Approved, Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salbutamol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Salbutamol.Withdrawn
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Salbutamol.Withdrawn
PimozideSalbutamol may increase the QTc-prolonging activities of Pimozide.Approved
PiretanideSalbutamol may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Salbutamol.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Salbutamol.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Salbutamol.Withdrawn
PolythiazideSalbutamol may increase the hypokalemic activities of Polythiazide.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Salbutamol.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Salbutamol.Approved
PrimaquineSalbutamol may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideSalbutamol may increase the QTc-prolonging activities of Procainamide.Approved
PromazineSalbutamol may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneSalbutamol may increase the QTc-prolonging activities of Propafenone.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Salbutamol.Approved
QuetiapineSalbutamol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneSalbutamol may increase the hypokalemic activities of Quinethazone.Approved
QuinidineSalbutamol may increase the QTc-prolonging activities of Quinidine.Approved
QuinineSalbutamol may increase the QTc-prolonging activities of Quinine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salbutamol.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Salbutamol.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Salbutamol.Withdrawn
SaquinavirSalbutamol may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Salbutamol.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Salbutamol.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Salbutamol.Approved
SotalolSalbutamol may increase the QTc-prolonging activities of Sotalol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Salbutamol.Approved
SulfisoxazoleSalbutamol may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
TamsulosinTamsulosin may decrease the vasoconstricting activities of Salbutamol.Approved, Investigational
TelavancinSalbutamol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinSalbutamol may increase the QTc-prolonging activities of Telithromycin.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Salbutamol.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Salbutamol.Experimental
TertatololTertatolol may decrease the bronchodilatory activities of Salbutamol.Experimental
TetrabenazineSalbutamol may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineSalbutamol may increase the QTc-prolonging activities of Thioridazine.Withdrawn
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Salbutamol.Approved
TimololTimolol may decrease the bronchodilatory activities of Salbutamol.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Salbutamol.Approved
TorasemideSalbutamol may increase the hypokalemic activities of Torasemide.Approved
ToremifeneSalbutamol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Salbutamol.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salbutamol.Approved
TrichlormethiazideSalbutamol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Salbutamol.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Salbutamol.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Salbutamol.Experimental
UrapidilUrapidil may decrease the vasoconstricting activities of Salbutamol.Investigational
VandetanibSalbutamol may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibSalbutamol may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Salbutamol.Approved
ZiprasidoneSalbutamol may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolSalbutamol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Toshikuni Kawazi, Masahiro Ono, Nobuko Inoue, "Salbutamol-containing plaster and method of producing same." U.S. Patent US5068103, issued February, 1984.

US5068103
General References
Not Available
External Links
Human Metabolome Database
HMDB01937
KEGG Drug
D02147
PubChem Compound
2083
PubChem Substance
46505312
ChemSpider
1999
BindingDB
25769
ChEBI
2549
ChEMBL
CHEMBL714
Therapeutic Targets Database
DNC000873
PharmGKB
PA448068
IUPHAR
558
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Wikipedia
Salbutamol
ATC Codes
R03AL02 — Salbutamol and ipratropium bromideR03AK04 — Salbutamol and sodium cromoglicateR03AC02 — SalbutamolR03CC02 — Salbutamol
AHFS Codes
  • 12:12.08.12
  • 48:12.04.12
PDB Entries
Not Available
FDA label
Not Available
MSDS
Download (52.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers3
1CompletedBasic SciencePulmonary Disease, Chronic Obstructive1
1CompletedDiagnosticAirway Inflammation1
1CompletedDiagnosticPulmonary Disease, Chronic Obstructive1
1CompletedDiagnosticSickle Cell Disorders1
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentAsthma Bronchial / Diabetes Mellitus (DM)1
1CompletedTreatmentAsthma, Allergic1
1CompletedTreatmentCongenital Myasthenic Syndrome1
1CompletedTreatmentDiabetes Mellitus (DM) / Healthy Volunteers1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentPompe's Disease1
1Not Yet RecruitingTreatmentAsthma Bronchial1
1RecruitingBasic ScienceCardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions1
1RecruitingTreatmentStatus Asthmaticus1
1, 2CompletedTreatmentPompe's Disease1
2CompletedBasic ScienceMemory Functions1
2CompletedDiagnosticLung Diseases, Obstructive1
2CompletedTreatmentAsthma Bronchial12
2CompletedTreatmentAsthma Bronchial / Bronchospasm1
2CompletedTreatmentAsthma Bronchial / Efficacy / Safety1
2CompletedTreatmentBrain Death / Organ Donors / Pulmonary Edemas1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentChronic Respiratory Failure / Clinically Significant Increase in Maximum Expiratory Volume Per Second1
2CompletedTreatmentPulmonary Disease, Chronic Obstructive2
2RecruitingTreatmentAsthma Bronchial1
2RecruitingTreatmentLymphangioleiomyomatosis1
2Unknown StatusTreatmentAsthma Bronchial1
2WithdrawnTreatmentIdiopathic Pulmonary Arterial Hypertension1
2, 3CompletedTreatmentAllergies1
2, 3TerminatedTreatmentRespiratory Distress Syndrome, Adult1
2, 3WithdrawnTreatmentCongestive Heart Failure (CHF)1
3CompletedTreatmentAllergies / Conjunctivitis / Rhinitis / Rhinoconjunctivitis2
3CompletedTreatmentAsthma Bronchial18
3CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentBronchial Asthma2
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)7
3CompletedTreatmentOrganophosphate Poisoning1
3CompletedTreatmentPersistent Asthma1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive5
3CompletedTreatmentReactive Airways Disease (RAD)1
3RecruitingTreatmentAsthma Bronchial2
3RecruitingTreatmentBronchial Asthma1
3RecruitingTreatmentCongestive Heart Failure (CHF) / Heart Failure, Left-Sided / Left-Sided Heart Failure1
3RecruitingTreatmentRhinitis, Allergic, Seasonal1
3TerminatedPreventionAsthma Bronchial / Bronchospasm1
3TerminatedTreatmentAsthma Bronchial1
3Unknown StatusTreatmentPulmonary Disease, Chronic Obstructive1
3WithdrawnTreatmentAsthma Bronchial1
3WithdrawnTreatmentAsthma Bronchial / Chronic Lung Diseases1
3WithdrawnTreatmentPulmonary Disease, Chronic Obstructive1
4Active Not RecruitingTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
4CompletedNot AvailableAsthma Bronchial2
4CompletedBasic ScienceAsthma Bronchial1
4CompletedBasic ScienceBronchoconstriction / Cycling Performance / Exercise-Induced Bronchoconstriction (EIB) / Inhaled Salbutamol1
4CompletedDiagnosticAsthma Bronchial1
4CompletedDiagnosticObliterative Bronchiolitis1
4CompletedHealth Services ResearchAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
4CompletedPreventionAsthma Bronchial / Heart Rate Fast1
4CompletedSupportive CareAsthma Bronchial1
4CompletedSupportive CareChronic Obstructive Pulmonary Disease (COPD) / Sepsis / Shock1
4CompletedTreatmentAcute Asthma / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAsthma Bronchial9
4CompletedTreatmentChildhood Asthma1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
4CompletedTreatmentPompe's Disease1
4CompletedTreatmentPulmonary Disease, Chronic Obstructive4
4Not Yet RecruitingTreatmentVentricular Septal Defects1
4RecruitingNot AvailableAsthma Bronchial / Food Allergy / Obstructive Sleep Apnea (OSA) / Viruses / Wheezing1
4RecruitingTreatmentAir Trapping / Airflow Limitation / Hyperinflation / Obstructive Lung Diseases / Secondhand Smoke / Tobacco1
4RecruitingTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentAsthmatic Bronchitis / Obstruction Airway / Wheezing / Wheezy Bronchitis1
4TerminatedTreatmentAcute Asthma1
4TerminatedTreatmentAsthma Bronchial1
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusDiagnosticChronic Lung Disease of Prematurity / Very Low Birth Weight1
4Unknown StatusPreventionCesarean Section / Postnatal Pulmonary Adaptation1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentBronchial Asthma1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4WithdrawnTreatmentAsthma Bronchial1
4WithdrawnTreatmentWheezing1
Not AvailableCompletedNot AvailableAsthma Bronchial / Chronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema1
Not AvailableCompletedBasic ScienceAdrenergic Beta-2 Agonist Effect / Adrenergic Beta-2 Agonist Effect in Healthy Subjects / Albuterol Effect / Albuterol Effect in Healthy Subjects1
Not AvailableCompletedBasic ScienceCystic Fibrosis (CF) / Healthy Volunteers1
Not AvailableCompletedBasic ScienceMuscle Hypertrophy in Healthy Young Men1
Not AvailableCompletedDiagnosticAsthma Bronchial1
Not AvailableCompletedDiagnosticBronchodilation1
Not AvailableCompletedDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedDiagnosticHematopoietic Stem Cell Transplantation (HSCT) / Obliterative Bronchiolitis1
Not AvailableCompletedHealth Services ResearchAsthma Bronchial1
Not AvailableCompletedHealth Services ResearchChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentAcute Asthma / Moderate and Severe Acute Asthma Exacerbations in Pediatric Patients1
Not AvailableCompletedTreatmentAsthma Bronchial2
Not AvailableCompletedTreatmentAsthma Bronchial / Children1
Not AvailableCompletedTreatmentAsthma Placebo Effects1
Not AvailableCompletedTreatmentAutoimmune Diseases / Disseminated Sclerosis1
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentMuscular Dystrophy1
Not AvailableCompletedTreatmentMuscular Dystrophy, Facioscapulohumeral1
Not AvailableCompletedTreatmentPneumonia1
Not AvailableCompletedTreatmentRespiratory Failure1
Not AvailableEnrolling by InvitationBasic ScienceOxygen Consumption1
Not AvailableNot Yet RecruitingDiagnosticChildhood Asthma1
Not AvailableNot Yet RecruitingTreatmentHigh Flow Nasal Cannula1
Not AvailableRecruitingNot AvailableAAT Deficiency / AATD / Alpha-1 Antitrypsin Deficiency / Cystic Fibrosis (CF)1
Not AvailableRecruitingNot AvailableAirway Disease Small / Hypersensitivity Pneumonitis1
Not AvailableRecruitingNot AvailableAortic Valve Stenosis / Hypertension,Essential / Impaired Renal Function / Secondary Hypertension1
Not AvailableRecruitingHealth Services ResearchAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingTreatmentAsthma Bronchial2
Not AvailableRecruitingTreatmentRespiratory Muscle Weakness / Spinal Cord Injuries (SCI)1
Not AvailableRecruitingTreatmentSevere Bronchopulmonary Dysplasia1
Not AvailableSuspendedTreatmentCystic Fibrosis (CF)1
Not AvailableTerminatedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusNot AvailableAsthma Bronchial1
Not AvailableUnknown StatusNot AvailableChronic Obstructive Pulmonary Disease (COPD) / Emphysema1
Not AvailableUnknown StatusNot AvailableElectrophysiological Parameters / Influence of Nebulized Bronchodilatators on Selected1
Not AvailableUnknown StatusNot AvailableErgogenic Effects of Salbutamol in Healthy Males1
Not AvailableUnknown StatusDiagnosticTuberculosis1
Not AvailableUnknown StatusTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentBronchiolitis1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)2
Not AvailableUnknown StatusTreatmentHeart Failure, Unspecified / Ischaemic Cardiomyopathy / Non-ischaemic Cardiomyopathy1

Pharmacoeconomics

Manufacturers
  • Armstrong pharmaceuticals inc
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Pliva inc
  • Schering corp sub schering plough corp
  • Glaxosmithkline
  • Teva global respiratory research llc
  • 3m pharmaceuticals inc
  • Dey lp
  • Actavis mid atlantic llc
  • Apotex inc richmond hill
  • Apotex inc
  • Bausch and lomb inc
  • Cobalt laboratories inc
  • Copley pharmaceutical inc
  • Hi tech pharmacal co inc
  • Holopack international
  • Landela pharmaceutical
  • Nephron pharmaceuticals corp
  • Nephron corp
  • Novex pharma
  • Roxane laboratories inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Amneal pharmaceuticals
  • Mova pharmaceuticals corp
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Vistapharm inc
  • Mylan pharmaceuticals inc
  • Muro pharmaceutical inc
  • Dava pharmaceuticals inc
  • American therapeutics inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Ucb inc
  • Warner chilcott div warner lambert co
  • Breath ltd
  • Sepracor inc
  • Teva Pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
Aerosol, meteredRespiratory (inhalation)100 mcg
Aerosol, meteredOral90 ug/1
TabletOral2 mg/1
TabletOral4 mg/1
SolutionIntrabronchial.63 mg/3mL
SolutionIntrabronchial1.25 mg/3mL
SolutionIntrabronchial2.5 mg/3mL
SolutionOral2 mg/5mL
SolutionRespiratory (inhalation).75 mg/3mL
SolutionRespiratory (inhalation).83 mg/mL
SolutionRespiratory (inhalation)1.5 mg/3mL
SolutionRespiratory (inhalation)2.5 mg/.5mL
SolutionRespiratory (inhalation)2.5 mg/3mL
SolutionRespiratory (inhalation)5 mg/mL
SyrupOcclusive dressing technique2 mg/5mL
SyrupOral2 mg/5mL
TabletOral2.4 mg/1
Tablet, film coated, extended releaseOral4 mg/1
Tablet, film coated, extended releaseOral8 mg/1
Tablet, extended releaseOral4 mg/1
Tablet, extended releaseOral8 mg/1
TabletOral2 mg
TabletOral4 mg
Aerosol, meteredOral; Respiratory (inhalation)
Spray, meteredRespiratory (inhalation)
InhalantRespiratory (inhalation)
SolutionRespiratory (inhalation)
SolutionRespiratory (inhalation).31 mg/3mL
SolutionRespiratory (inhalation).63 mg/3mL
SolutionRespiratory (inhalation)1.25 mg/.5mL
SolutionRespiratory (inhalation)1.25 mg/3mL
Aerosol, meteredOral100 mcg
SolutionOral0.4 mg
SolutionOral; Respiratory (inhalation)5 mg
SolutionRespiratory (inhalation)0.5 mg
Powder, meteredRespiratory (inhalation)90 ug/1
SolutionRespiratory (inhalation)5 mg
LiquidRespiratory (inhalation)1 mg
LiquidRespiratory (inhalation)0.05 %
LiquidRespiratory (inhalation)0.1 %
LiquidRespiratory (inhalation)0.2 %
SolutionRespiratory (inhalation)1 mg
SolutionRespiratory (inhalation)2 mg
PowderRespiratory (inhalation)400 mcg
PowderRespiratory (inhalation)200 mcg
Aerosol, meteredRespiratory (inhalation)108 ug/1
Aerosol, meteredRespiratory (inhalation)90 ug/1
SolutionIntramuscular0.5 mg
SolutionIntravenous0.25 mg
SolutionIntravenous1 mg
LiquidIntramuscular.5 mg
LiquidIntravenous1 mg
LiquidIntravenous.25 mg
SolutionRespiratory (inhalation)2.5 mg
LiquidRespiratory (inhalation)1.25 mg
LiquidRespiratory (inhalation)2.5 mg
SolutionRespiratory (inhalation)1.25 mg
LiquidRespiratory (inhalation)5 mg
LiquidOral0.4 mg
LiquidOral.4 mg
CapsuleRespiratory (inhalation)200 mcg
CapsuleRespiratory (inhalation)400 mcg
Solution, concentrateRespiratory (inhalation)1.25 mg/.5mL
Aerosol, meteredOral45 ug/1
Prices
Unit descriptionCostUnit
Xopenex 0.63 mg/3 ml solution64.2USD ml
Proventil HFA 108 (90 Base)mcg/act Aerosol 6.7 gm Inhaler55.09USD inhaler
Xopenex HFA 45 mcg/act Aerosol 15 gm Inhaler53.84USD inhaler
AccuNeb 0.63 mg/3ml Neb. Solution 1 Box= 25 Vials53.14USD plastic
AccuNeb 1.25 mg/3ml Neb. Solution 1 Box= 25 Vials53.14USD plastic
ProAir HFA 108 (90 Base)mcg/act Aerosol 8.5 gm Inhaler45.99USD inhaler
Ventolin HFA 108 (90 Base)mcg/act Aerosol 18 gm Inhaler39.99USD inhaler
Proair hfa 90 mcg inhaler12.62USD g
Proventil hfa 90 mcg inhaler8.07USD g
Xopenex hfa 45 mcg inhaler6.12USD g
Xopenex 0.31 mg/3ml (1 Box = 24, 3ml Vials)4.87USD plastic
Xopenex 1.25 mg/3ml (1 Box = 24, 3ml Vials)4.87USD plastic
Xopenex 0.63 mg/3ml (1 Box = 24, 3ml Vials)4.71USD plastic
Xopenex 1.25 mg/3 ml solution2.96USD ml
Ventolin hfa 90 mcg inhaler2.01USD g
Xopenex 0.31 mg/3 ml solution1.56USD ml
Ventolin 5 mg/ml Solution1.13USD ml
Ventolin Nebules P.F. 2 mg/ml Unit Dose Solution0.88USD ml
Accuneb 0.63 mg/3 ml inh solution0.68USD ml
Accuneb 1.25 mg/3 ml inh solution0.68USD ml
Mylan-Salbutamol 5 mg/ml Solution0.62USD ml
Pms-Salbutamol 5 mg/ml Solution0.62USD ml
Ratio-Salbutamol 5 mg/ml Solution0.62USD ml
Sandoz Salbutamol 5 mg/ml Solution0.62USD ml
Mylan-Salbutamol Sterinebs P.F. 2 mg/ml Unit Dose Solution0.48USD ml
Pms-Salbutamol Polyneb 2 mg/ml Unit Dose Solution0.48USD ml
Ratio-Salbutamol Uni Dose P.F. 2 mg/ml Unit Dose Solution0.48USD ml
Ventolin Nebules P.F. 1 mg/ml Solution0.47USD ml
Mylan-Salbutamol Sterinebs P.F. 1 mg/ml Solution0.25USD ml
Pms-Salbutamol 1 mg/ml Solution0.25USD ml
Ratio-Salbutamol Sulf U.D.P.F. 1 mg/ml Solution0.25USD ml
Apo-Salvent 4 mg Tablet0.22USD tablet
Pms-Salbutamol 0.5 mg/ml Solution0.16USD ml
Ratio-Salbutamol Unit Dose P.F 0.5 mg/ml Solution0.16USD ml
Apo-Salvent 2 mg Tablet0.13USD tablet
Pms-Salbutamol 400 mcg/ml Liquid0.05USD ml
Ratio-Salbutamol Hfa 100 mcg/dose Metered Dose Aerosol0.04USD dose
Airomir Cfc-Free 100 mcg/dose Metered Dose Aerosol0.03USD dose
Apo-Salvent Cfc Free 100 mcg/dose Metered Dose Aerosol0.03USD dose
Ventolin Hfa 100 mcg/dose Metered Dose Aerosol0.03USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6352684No1992-11-282009-11-28Us
CA2125667No2000-03-132012-12-04Canada
CA2125665No2001-06-122012-12-04Canada
US5775321No1995-07-072015-07-07Us
US6451289No2001-03-212021-03-21Us
US6446627No1997-12-182017-12-18Us
US6702997No2001-12-282021-12-28Us
US6632842No2001-12-282021-12-28Us
US6558651Yes1997-06-192017-06-19Us
US6743413Yes2001-12-012021-12-01Us
US6938796Yes1998-07-162018-07-16Us
US6997349Yes1998-07-162018-07-16Us
US6431168Yes1998-12-082018-12-08Us
US7107986Yes1998-12-062018-12-06Us
US7500444Yes2006-08-262026-08-26Us
US6315173Yes1998-06-232018-06-23Us
US7143908Yes1998-07-162018-07-16Us
US6170717Yes1998-06-232018-06-23Us
US7350676Yes1999-02-242019-02-24Us
US7832351Yes2003-12-192023-12-19Us
US6161724Yes1998-07-162018-07-16Us
US6510969Yes1998-06-232018-06-23Us
US6966467Yes1998-06-232018-06-23Us
US6435372Yes1998-07-162018-07-16Us
US7566445No1997-06-042017-06-04Us
US8834849No1997-06-042017-06-04Us
US7105152No2003-09-122023-09-12Us
US8132712No2008-09-072028-09-07Us
US6006745No1996-12-282016-12-28Us
US7256310No2004-10-082024-10-08Us
US8765153No2003-12-082023-12-08Us
US5836299No1995-11-172015-11-17Us
US6453795Yes1997-06-052017-06-05Us
US8733341Yes2011-04-162031-04-16Us
US9027967Yes2007-10-012027-10-01Us
US7104470Yes1997-04-042017-04-04Us
US7246615Yes1996-12-012016-12-01Us
US7896264Yes2005-11-262025-11-26Us
US7988001Yes2002-02-042022-02-04Us
US7802568Yes1999-08-262019-08-26Us
US6149054Yes1997-06-162017-06-16Us
US6726124Yes1997-04-042017-04-04Us
US7396341Yes2007-04-102027-04-10Us
US6846413Yes1999-02-282019-02-28Us
US6176442Yes1996-12-012016-12-01Us
US7837235Yes2008-09-132028-09-13Us
US5964416Yes1997-04-042017-04-04Us
US7284474Yes2005-02-262025-02-26Us
US6977042Yes1999-02-282019-02-28Us
US6988496Yes2000-08-232020-08-23Us
US6871646No2001-06-232021-06-23Us
US8978966No2012-01-132032-01-13Us
US6701917No2001-06-232021-06-23Us
US7540282No2003-05-062023-05-06Us
US6748947No2001-06-232021-06-23Us
US8006690No2001-06-232021-06-23Us
US6718972No2001-06-232021-06-23Us
US9216260No2011-06-282031-06-28Us
US8651103No2008-03-262028-03-26Us
US9463289No2011-05-182031-05-18Us
US9463288No2005-05-192025-05-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)147-149Lunts, L.H.C. and Toon, P.; U.S. Patent 3,644,353; February 22,1972; assigned to Allen & Hanburys Ltd.
water solubility1.41E+004 mg/LYALKOWSKY,SH & HE,Y (2003)
logP1.4Not Available
logS-1.22ADME Research, USCD
pKa10.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.15 mg/mLALOGPS
logP0.44ALOGPS
logP0.34ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)10.12ChemAxon
pKa (Strongest Basic)9.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity67.87 m3·mol-1ChemAxon
Polarizability26.86 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9812
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7112
P-glycoprotein substrateSubstrate0.684
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.9673
Renal organic cation transporterNon-inhibitor0.8974
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7074
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9197
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9287
CYP450 3A4 inhibitorNon-inhibitor0.9343
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8834
Ames testNon AMES toxic0.8409
CarcinogenicityNon-carcinogens0.8863
BiodegradationNot ready biodegradable0.9734
Rat acute toxicity2.5275 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9564
hERG inhibition (predictor II)Non-inhibitor0.9288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-afe3df5bdead805eacaf
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-1d8b235dd1e02960dba1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00dr-0090000000-6fee6c25dfbf9c3a7c13
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0290000000-0d38029df88ee8018d9a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00kf-0950000000-9572451e9f596ae94494
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-05c59c5c9d63de269feb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-8ef6b84074e243e637bd
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00dr-0090000000-e288fafc6755fa4abcba
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0290000000-5569e08c145733118852
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0296-0940000000-f3558c829fecc8fea6f0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0900000000-9b7ad78396782fd2237d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-19973e6238f364b40ec6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dl-0190000000-bec72774da692a955281
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-9d1b7a0e974ab4c5c2cf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-98cef35812448be3e2db
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006x-0090000000-182d7b602151e8ac7849
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006t-0950000000-935c99cfc4690ce298f1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-064806e46a30b7dd760b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-6acca58ec4a7b6892bb1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-007k-1900000000-6b18a64209aa89c42af0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ec-4900000000-70c609482357e411ae42
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006x-0090000000-127c8a78dd75e131e46a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006t-0950000000-a3cef97d0495f36363a5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-af9a8ad8ae6e7ade3b9b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-c95568abe549433d67e8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-007k-1900000000-06178e64d95e7221bccb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00ec-4900000000-339502da9d74d89569f0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-039f3f4bbefe1a1588d8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006x-0190000000-99e78b87fa74322fae1d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-637588735361fe2a9ad0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-007k-1900000000-b19c47ea3e07181932ab
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-009x-7900000000-6091051edb1a5c40218e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002f-9400000000-ff279a7ba0390c8a14df
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00r2-0930000000-00b798f29eb25b7a4565

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzyl alcohols. These are organic compounds containing the phenylmethanol substructure.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzyl alcohols
Direct Parent
Benzyl alcohols
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Benzyl alcohol / Phenol / Aralkylamine / 1-hydroxy-2-unsubstituted benzenoid / Secondary alcohol / 1,2-aminoalcohol / Secondary amine / Secondary aliphatic amine / Hydrocarbon derivative / Alcohol
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
phenylethanolamines, phenols, secondary amino compound (CHEBI:2549)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Brichetto L, Milanese M, Song P, Patrone M, Crimi E, Rehder K, Brusasco V: Beclomethasone rapidly ablates allergen-induced beta 2-adrenoceptor pathway dysfunction in human isolated bronchi. Am J Physiol Lung Cell Mol Physiol. 2003 Jan;284(1):L133-9. Epub 2002 Aug 16. [PubMed:12388338]
  2. Chong LK, Suvarna K, Chess-Williams R, Peachell PT: Desensitization of beta2-adrenoceptor-mediated responses by short-acting beta2-adrenoceptor agonists in human lung mast cells. Br J Pharmacol. 2003 Feb;138(3):512-20. [PubMed:12569076]
  3. Yamanishi T, Chapple CR, Yasuda K, Yoshida K, Chess-Williams R: Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourol Urodyn. 2003;22(4):338-42. [PubMed:12808710]
  4. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145]
  5. Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, Torres A, Gorman JD, Salari K, Rodriguez-Santana JR, Toscano M, Sylvia JS, Alioto M, Castro RA, Salazar M, Gomez I, Fagan JK, Salas J, Clark S, Lilly C, Matallana H, Selman M, Chapela R, Sheppard D, Weiss ST, Ford JG, Boushey HA, Drazen JM, Rodriguez-Cintron W, Silverman EK, Burchard EG: Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med. 2005 Mar 15;171(6):563-70. Epub 2004 Nov 19. [PubMed:15557128]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Baker JG: The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005 Feb;144(3):317-22. [PubMed:15655528]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:50